Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Generic versus branded pharmacotherapy in Parkinson's disease: does it matter? A review.

Go CL, Rosales RL, Schmidt P, Lyons KE, Pahwa R, Okun MS.

Parkinsonism Relat Disord. 2011 Jun;17(5):308-12. doi: 10.1016/j.parkreldis.2011.02.005. Review.

PMID:
21367644
2.

Generic substitution in the treatment of epilepsy: patient and physician perceptions.

Berg MJ, Gross RA, Haskins LS, Zingaro WM, Tomaszewski KJ.

Epilepsy Behav. 2008 Nov;13(4):693-9. doi: 10.1016/j.yebeh.2008.06.001.

PMID:
18589000
3.

Bioequivalence and other unresolved issues in generic drug substitution.

Meredith P.

Clin Ther. 2003 Nov;25(11):2875-90.

PMID:
14693311
4.

Current approaches to the use of generic antiepileptic drugs.

Krämer G, Biraben A, Carreno M, Guekht A, de Haan GJ, Jedrzejczak J, Josephs D, van Rijckevorsel K, Zaccara G.

Epilepsy Behav. 2007 Aug;11(1):46-52. Review.

PMID:
17537678
5.

The generics in transplantation and the rules on their use.

Masri M.

Exp Clin Transplant. 2003 Jun;1(1):65-8.

6.

Drug substitution in transplantation: a National Kidney Foundation White Paper.

Sabatini S, Ferguson RM, Helderman JH, Hull AR, Kirkpatrick BS, Barr WH.

Am J Kidney Dis. 1999 Feb;33(2):389-97. Review.

PMID:
10023656
7.

Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability.

Bialer M, Midha KK.

Epilepsia. 2010 Jun;51(6):941-50. doi: 10.1111/j.1528-1167.2010.02573.x. Review.

8.

A physician survey on generic drugs and substitution of critical dose medications.

Banahan BF 3rd, Kolassa EM.

Arch Intern Med. 1997 Oct 13;157(18):2080-8.

PMID:
9382664
9.

The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence.

Duh MS, Cahill KE, Paradis PE, Cremieux PY, Greenberg PE.

Expert Opin Pharmacother. 2009 Oct;10(14):2317-28. doi: 10.1517/14656560903140525. Review.

PMID:
19663636
10.

Report of the American Society of Transplantation conference on immunosuppressive drugs and the use of generic immunosuppressants.

Alloway RR, Isaacs R, Lake K, Hoyer P, First R, Helderman H, Bunnapradist S, Leichtman A, Bennett MW, Tejani A, Takemoto SK.

Am J Transplant. 2003 Oct;3(10):1211-5.

11.

Generic low-molecular-weight heparins: some practical considerations.

Fareed J, Leong WL, Hoppensteadt DA, Jeske WP, Walenga J, Wahi R, Bick RL.

Semin Thromb Hemost. 2004 Dec;30(6):703-13. Review.

PMID:
15630677
12.

Prescribing generic antiepileptic drugs: Issues and concerns for nurse practitioners.

Barrett MW.

J Am Acad Nurse Pract. 2010 Jun;22(6):300-4. doi: 10.1111/j.1745-7599.2010.00511.x. Review.

PMID:
20536627
13.
14.

Costs of Parkinson's disease and antiparkinsonian pharmacotherapy: an Italian cohort study.

Winter Y, von Campenhausen S, Reese JP, Balzer-Geldsetzer M, Longo K, Spiga G, Boetzel K, Eggert K, Oertel WH, Dodel R, Barone P.

Neurodegener Dis. 2010;7(6):365-72. doi: 10.1159/000302644.

PMID:
20523028
15.

Descriptive study and pharmacotherapeutic intervention in patients with epilepsy or Parkinson's disease at nursing homes in southern Sweden.

Midlöv P, Bondesson A, Eriksson T, Petersson J, Minthon L, Höglund P.

Eur J Clin Pharmacol. 2002 Feb;57(12):903-10.

PMID:
11936711
16.

Treatment benefit and daily drug costs associated with treating Parkinson's disease in a Parkinson's disease clinic.

Müller T, Voss B, Hellwig K, Josef Stein F, Schulte T, Przuntek H.

CNS Drugs. 2004;18(2):105-11.

PMID:
14728057
17.

Healthcare costs in renal transplant recipients using branded versus generic ciclosporin.

Helderman JH, Kang N, Legorreta AP, Chen JY.

Appl Health Econ Health Policy. 2010;8(1):61-8. doi: 10.2165/11530720-000000000-00000.

PMID:
20038194
18.

Selegiline shortage: Causes and costs of a generic drug shortage.

Dorsey ER, Thompson JP, Dayoub EJ, George B, Saubermann LA, Holloway RG.

Neurology. 2009 Jul 21;73(3):213-7. doi: 10.1212/WNL.0b013e3181ae7b04.

19.

Costs of drug treatment in Parkinson's disease.

Dodel RC, Eggert KM, Singer MS, Eichhorn TE, Pogarell O, Oertel WH.

Mov Disord. 1998 Mar;13(2):249-54.

PMID:
9539337
20.

Transplant pharmacists' opinions on generic product selection of critical-dose drugs.

Vasquez EM, Min DI.

Am J Health Syst Pharm. 1999 Apr 1;56(7):615-21.

PMID:
10423207
Items per page

Supplemental Content

Support Center